Wall Street analysts forecast that NeuBase Therapeutics, Inc. (NASDAQ:NBSE) will report ($0.27) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for NeuBase Therapeutics’ earnings. The lowest EPS estimate is ($0.27) and the highest is ($0.26). NeuBase Therapeutics posted earnings of ($0.20) per share in the same quarter last year, which would suggest a negative year over year growth rate of 35%. The business is scheduled to announce its next quarterly earnings results on Wednesday, December 22nd.
According to Zacks, analysts expect that NeuBase Therapeutics will report full-year earnings of ($0.95) per share for the current financial year, with EPS estimates ranging from ($0.99) to ($0.88). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.03) per share, with EPS estimates ranging from ($1.34) to ($0.87). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover NeuBase Therapeutics.
NeuBase Therapeutics (NASDAQ:NBSE) last announced its quarterly earnings results on Thursday, August 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05).
Shares of NASDAQ NBSE opened at $3.89 on Monday. NeuBase Therapeutics has a 12-month low of $3.26 and a 12-month high of $12.89. The company has a market capitalization of $127.27 million, a PE ratio of -4.27 and a beta of -0.01. The firm’s 50-day moving average is $3.72 and its two-hundred day moving average is $4.67.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its position in NeuBase Therapeutics by 5.4% during the first quarter. JPMorgan Chase & Co. now owns 51,222 shares of the company’s stock worth $379,000 after purchasing an additional 2,641 shares during the last quarter. Heritage Wealth Advisors increased its position in shares of NeuBase Therapeutics by 80.0% in the second quarter. Heritage Wealth Advisors now owns 9,000 shares of the company’s stock worth $63,000 after acquiring an additional 4,000 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of NeuBase Therapeutics by 5.2% in the second quarter. Goldman Sachs Group Inc. now owns 109,685 shares of the company’s stock worth $525,000 after acquiring an additional 5,450 shares in the last quarter. Royal Bank of Canada increased its position in shares of NeuBase Therapeutics by 121.1% in the first quarter. Royal Bank of Canada now owns 11,244 shares of the company’s stock worth $83,000 after acquiring an additional 6,158 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in NeuBase Therapeutics during the 2nd quarter valued at $33,000. 31.85% of the stock is currently owned by institutional investors and hedge funds.
NeuBase Therapeutics Company Profile
NeuBase Therapeutics, Inc is a biotechnology company. It engages in the development of drugs for patients with genetic neurological disorder. The firms pipelines include Huntington’s Disease, NT0100 Program – PATrOL Enabled gamma-PNA for Huntington’s Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy.
Recommended Story: How is the S&P 500 index different from the DJIA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.